AstraZeneca, european medicines agency and lung cancer
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed a feedback from the European Medicines Agency, the pharma company said Tuesday.
European markets are set to open higher on Tuesday, in a shortened trading session for Christmas Eve. London's FTSE 100 is ...
A once-groundbreaking sickle cell disease drug — at the center of a $5.4 billion acquisition two years ago — is the subject ...
Anavex (AVXL) stock rallied 30% Monday after the company announced EU regulators had accepted the market application for its ...
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...
Cytokinetics (CYTK) announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, MAA, for ...
Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback